All In MedTech

Device Trial Radar · NCT07312383

Skin Microcirculation in Patients With Lower Limb Atherosclerosis

Last checked: Nov 20, 2026Latest source record: Aug 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Dec 15, 2025

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
ODI Medical ASNot on our public-company list
Sponsor type
Industry
First posted
Dec 31, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The aim of this study is to explore the ability of the non-invasive device ODI-Tech® to monitor changes in microvascular blood flow in patients with lower limb ischemia undergoing the procedure percutaneous transluminal angioplasty (PTA). Microvascular data from patients and healthy case matched controls at baseline will be compared.15 patients and 15 healthy case matched controls will be enrolled.

Conditions

  • Percutaneous Transluminal Angioplasty
  • Atherosclerosis of Arteries of the Extremities, Unspecified

Interventions

  • Examination with the ODI-Tech medical deviceDevice

    Diffuse reflectance spectroscopy and computer-assisted microscopy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes in skin microvascular oxygen saturation (SmvO2)Time frame: From baseline to 40 days post PTA

1 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Oslo University Hospital

    Oslo, Norway · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.